Description:
GOG-0241 Follow-Up Form (Q) Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8D161DC6-F374-44EE-E040-BB89AD431853
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8D161DC6-F374-44EE-E040-BB89AD431853Keywords:
Versions (3)
- 9/19/12 9/19/12 -
- 1/9/15 1/9/15 - Martin Dugas
- 1/9/15 1/9/15 - Martin Dugas
Uploaded on:
January 9, 2015
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Fallopian Tube Cancer NCT01081262 Follow-Up - GOG-0241 Follow-Up Form (Q) - 3126299v1.0
No Instruction available.
- StudyEvent: GOG-0241 Follow-Up Form (Q)